Acute Charcot foot remains one of the most disabling complications of diabetic neuropathy. While classically rare, a new nationwide study from Denmark suggests that its story is more nuanced than previously thought: See Ahmed 2025 Incidence of Charcot in Denmark.
From 2000 to 2021, researchers tracked more than 265,000 patients with diabetes across Denmark and found a paradoxical trend: although the absolute number of Charcot cases rose significantly (Kendall’s tau = 0.6, p < 0.0005), the incidence rate per capita among people with diabetes actually declined (Kendall’s tau = -0.6, p = 0.0005).
This tells us two things. First, the increasing prevalence of diabetes globally continues to put more individuals at risk. But second, improved management of diabetes and neuropathy may be successfully reducing the individual risk of developing Charcot foot.
Notably, there were no significant regional differences in incidence across Denmark’s five health regions, nor was there any measurable impact from the COVID-19 pandemic or the nurses’ strike of 2021—a testament to the country’s resilient multidisciplinary care infrastructure.
While early detection and off-loading remain the mainstay of treatment, these findings underscore the importance of public health infrastructure in mitigating the disabling effects of diabetic complications.
Leave a Reply